Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats.

The ascites hepatoma Yoshida AH-130 induces loss of body weight and tissue waste. Tumour necrosis factor alpha (TNF-alpha) plays a pivotal role in the pathogenesis of muscle wasting in this model system, but other cytokines, such as interleukin-6, may be involved. In order to verify whether a combined anticytokine treatment may synergistically counteract muscle protein degradation, tumour bearing rats were treated with pentoxyfilline (PTX, an inhibitor of TNF-alpha synthesis), or with suramin (SUR, an antiprotozoal drug blocking the peripheral action of several cytokines including IL-6 and TNF-alpha), or both the drugs, and the effects on muscle proteolytic systems were assessed. Muscle protein loss in the AH-130-bearing rats was associated with increased activity of both the ATP-ubiquitin- and the calpain- dependent proteolytic pathways (246% and 230% of controls, respectively). Both PTX and SUR, either alone or in combination, prevented the depletion of muscle mass and significantly reduced the activity of muscle proteolytic systems. In particular, treatment with SUR, either alone or with PTX, induced a decrease in enzymatic activities to values similar to those of controls. The results obtained in the present paper demonstrate that: (i) muscle depletion in this model is indeed associated with increased proteasome- and calpain-dependent proteolysis, as previously suggested by increased mRNA expression of molecules pertaining to both pathways; (ii) anticytokine treatments effectively reduce muscle protein loss by down-regulating the activity of at least two major proteolitic systems; (iii) SUR is more effective than PTX in reducing the activity of proteolytic systems, possibly because of its multiple anticytokine action.

[1]  R. Bellantone,et al.  Increased muscle ubiquitin mRNA levels in gastric cancer patients. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[2]  P. Costelli,et al.  Activation of Ca2+-dependent proteolysis in skeletal muscle and heart in cancer cachexia , 2001, British Journal of Cancer.

[3]  M. Tisdale,et al.  Loss of skeletal muscle in cancer: biochemical mechanisms. , 2001, Frontiers in bioscience : a journal and virtual library.

[4]  J. Fischer,et al.  Muscle Cachexia: Current Concepts of Intracellular Mechanisms and Molecular Regulation , 2001, Annals of surgery.

[5]  R. Bellantone,et al.  Serum tumour necrosis factor‐α levels in cancer patients are discontinuous and correlate with weight loss , 2000, European journal of clinical investigation.

[6]  P. Costelli,et al.  Cancer cachexia: from experimental models to patient management. , 2000, Current opinion in clinical nutrition and metabolic care.

[7]  C. Martínez-A,et al.  Implication of calpain in caspase activation during B cell clonal deletion , 1999, The EMBO journal.

[8]  Keiji Tanaka,et al.  Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats , 1999, Molecular Biology Reports.

[9]  F. López‐Soriano,et al.  Tumour growth and nitrogen metabolism in the host (Review). , 1999, International journal of oncology.

[10]  N. Agell,et al.  Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. , 1998, Cancer letters.

[11]  N. Agell,et al.  Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice , 1998, Molecular and Cellular Endocrinology.

[12]  G. Cohen,et al.  Proteasome activities decrease during dexamethasone-induced apoptosis of thymocytes. , 1998, The Biochemical journal.

[13]  L. Tessitore,et al.  Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. , 1996, Biochemical and biophysical research communications.

[14]  S. Khera,et al.  Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines. , 1996, Leukemia & lymphoma.

[15]  G. Strassmann,et al.  Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy. , 1995, Cytokines and molecular therapy.

[16]  L. Tessitore,et al.  Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. , 1995, The Journal of clinical investigation.

[17]  A. Goldberg,et al.  Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. , 1995, The American journal of physiology.

[18]  N. Agell,et al.  Muscle wasting associated with cancer cachexia is linked to an important activation of the atp‐dependent ubiquitin‐mediated proteolysis , 1995, International journal of cancer.

[19]  J. Estrela,et al.  Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. , 1994, Cancer research.

[20]  L. Tessitore,et al.  Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. , 1993, The Journal of clinical investigation.

[21]  R. Nordan,et al.  Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. , 1993, The Journal of clinical investigation.

[22]  D. Breuillé,et al.  Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. , 1993, The American journal of physiology.

[23]  L. Tessitore,et al.  Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. , 1993, Archives of biochemistry and biophysics.

[24]  P Ghezzi,et al.  Suramin induces deoligomerization of human tumor necrosis factor alpha. , 1993, The Journal of biological chemistry.

[25]  M. Koohmaraie Ovine skeletal muscle multicatalytic proteinase complex (proteasome): purification, characterization, and comparison of its effects on myofibrils with mu-calpains. , 1992, Journal of animal science.

[26]  M. Muscaritoli,et al.  Abnormal substrate metabolism and nutritional strategies in cancer management. , 1991, JPEN. Journal of parenteral and enteral nutrition.

[27]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[28]  S. Warren THE IMMEDIATE CAUSES OF DEATH IN CANCER , 1932 .

[29]  T. Ogihara,et al.  Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model , 1999, Gene Therapy.

[30]  L. Tessitore,et al.  Anti-tumour necrosis factor-alpha treatment interferes with changes in lipid metabolism in a tumour cachexia model. , 1994, Clinical science.

[31]  G. Opdenakker,et al.  Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. , 1991, European journal of cancer.

[32]  W. Dewys Weight loss and nutritional abnormalities in cancer patients: incidence, severity and significance , 1986 .